Providence Medical Technology has received US Food and Drug Administration (FDA) 510(k) clearance for its CORUS Posterior Cervical Stabilization System 3D-T (CORUS PCSS 3D-T), a next-generation version of the company's posterior cervical fusion (PCF) implant produced with additive manufacturing in porous titanium. The company announced on October 29 that surgeons in California and Virginia have completed the first commercial procedures with the device. The device is indicated for patients with cervical degenerative disc disease, serving as a supplement to PCF to stabilize spinal segments, and is placed on both sides of the spine via a posterior approach. Building on the core design of the earlier CORUS PCSS, it adds a proprietary titanium lattice structure modeled on cancellous bone within the body, with porosity and pore size consistent with published bone ingrowth research. According to the company, the lattice distributes loads evenly and provides structural support during fusion. Compared with the original machined implant, the 3D-printed version offers 1.5 times the surface area and 8 times the surface roughness, and leaves room for packing bone graft material inside the device. The earlier CORUS PCSS was evaluated in a randomized clinical trial (NCT04229017); when used in combination with multilevel anterior fusion, it showed higher fusion rates at 12 and 24 months and a significantly lower two-year surgical revision rate than anterior fusion alone, with interim results published in Spine in May 2025. Providence has not yet reported comparable clinical results for the 3D-printed version. The first commercial procedures were performed by orthopedic spine surgeons Mohsin Fidai at Adventist Health White Memorial in Los Angeles and Abilio Reis at Bon Secours Memorial Regional Medical Center in Mechanicsville, Virginia. The 3D-printed implant is built with a porous titanium lattice for full-segment fusion.